Business, energy, technology, markets and global industry news from Business News Today

Phase II

PharmaDeviceNews Phase II
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More
Pharma & Biotech

Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?

Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.

Read More
Pharma & Biotech

Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?

Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.

Read More